Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD
Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. Some of the key highlights related to atopic dermatitis (AD) therapies include: APG777 APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13. APG777 demonstrates a 77-day half-life in a 12-month update from the Phase 1 study […]